Increased survival of IDH1/2^MT patients (A) in a glioblastoma population, (B) but not in a myeloid neoplasm population sequenced and analyzed by our groups. (C) IDH1^MT radiosensitize carcinoma cells and (D) IDH1^MT inhibitors radioprotect carcinoma cells.